Farmas USA

Joer, pues quito la orden mejor.

[borrado, mejor asi]

THLD

A 4,20.. Framus...!!!

Solofarmas, tú también tienes un punto kamikaze que es demasiao ¿eh?

Pero si te esta diciendo, compra...compra...compra.
Bueno veremos como va esto, pero a eso de comprar fortalece esta bien en aquellas que no han subido un 500%
De cualquier forma aquellas que caen en picado por AC recuperan al final.

MSTX
Por casualidad alquien la sigue, tiene mas referencia de AF, La tengo en WList desde hace mas de un año, tiene un soporte en lo actuales valores de tambien mas de un año y una resitencia por encima de 1.12 es decir un recorrido de facil un 100% desde ahora, coincido con este articulo dado la ventaja que ofrecen las OD, de 7 años de monopolio en este caso en USA + UE.
Comprar cuando estan dormidas y en soportes de larga plazo ( SUELO DURMIENTE ) es muy recomendable si les acompaña buen AF y los catalizadores no estan demasiado lejos que aburran.
Agradezco sugerencia y opiniones,
----
The current selloff in biotech space is a bargain picking opportunity.
Mast Therapeutics has shed 17% in one month despite having an orphan drug candidate for sickle cell disease entering Phase III trials, and being adequately funded.
The same candidate has an ODD for acute limb ischemia.
The market has also ignored acquisition by the company of another orphan drug for pulmonary arterial hypertension.

Mast Therapeutics (NYSEMKT:MSTX), a microcap biotech, is significantly undervalued, based on the fact that more than 50% of its value is in cash, and it has 2 orphan drug designations for its lead product candidate vepoloxamer (MST-188) for two separate indications, and its other candidate AIR001, also an orphan drug designee, reported positive top line results from its phase 2 study of pulmonary arterial hypertension ('PAH). Recently, the company also announced that it plans to develop its lead product candidate in chronic heart failure. If even one of these studies helps get a product into the market, we will see tremendous upside in the stock. MST-188 is in trial for both sickle cell disease and acute lower limb ischemia (ALI). Both these diseases, as well as PAH, have a lot of competition from the big players. That might look bad on the surface, but given the advanced positioning of MSTX in its pipeline progress, and its relatively low valuation at present, MSTX is actually a good candidate for acquisition by the likes of Pfizer or Baxter, with their own SCD programs.
http://seekingalpha.com/article/3051356-mast-therapeutics-small-cap-biotech-stock-with-big-potential

Mensual a fecha Julio 2015

--
http://finviz.com/quote.ashx?t=MSTX&ty=c&ta=0&p=w
-
Mast Therapeutics, Inc. (NYSEMKT:MSTX): The stock price is expected to reach $ 2 in the short term. The number of analysts agreeing with this consensus is 2. The higher estimate for the short term price target is at $3 while the lower estimate is at $1. The standard deviation of the price stands at $1.41. The company shares have dropped 16.95% in the past 52 Weeks. On September 8, 2014
The shares registered one year high of $0.69 and one year low was seen on November 6, 2014 at $0.4.
The 50-day moving average is $0.5 and the 200 day moving average is recorded at $0.5.
S&P 500 has rallied 7.62% during the last 52-weeks

Bueno, es lo que pienso.

La cuña que me habia dibujado tenia para hoy como limite inferior los 4,24 .. y acaba de tocar los 4,19 ... toca esperar ... de todos modos no tengo cash y tendria que vender unas NVAX que por debajo de 13$ no lo voy hacer, es mi minimo.

 

THLD